SCHEMBL13664227

SCHEMBL13664227

N#Cc1c(C(=O)c2ccc(Cl)s2)nn(-c2ccc(Cl)cc2)c1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
GAA P10253 2/20 0.46
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MELK Q14680 5/20 0.43
LMNA P02545 3/20 0.41
CNR1 P21554 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
CHEK1 O14757 1/20 0.37
KCNH2 Q12809 1/20 0.37
F2 P00734 1/20 0.37
CYP2C9 P11712 1/20 0.36
PPARG P37231 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13664174 0.81 MAPT (0.52) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664223 0.81 MAPT (0.52) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664224 0.80 MAPT (0.51) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664182 0.80 MAPT (0.51) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664179 0.79 MAPT (0.50) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664161 0.79 MAPT (0.51) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664168 0.79 MAPT (0.50) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664177 0.79 MAPT (0.50) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664246 0.77 MAPT (0.48) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664217 0.77 MAPT (0.49) MAPTMEN1KMT2ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists GIPR, GPR119, GLP1R MAPT 4701/4885MEN1 3462/4885KMT2A 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.